Abstract
Crohns disease and ulcerative colitis are complex diseases that have required the use of multiple modalities to aid in treatment. With an increasing understanding of the underlying pathogenetic mechanisms and identification of specific therapeutic targets, monoclonal antibody treatment has been an ideal strategy for inducing and maintaining remission in these patients. This article addresses approved agents and the supporting data justifying their use in Crohns disease and ulcerative colitis, the safety of and immunologic reactions to these agents, as well as newer agents for treatment.
Original language | English |
---|---|
Pages (from-to) | 607-620 |
Number of pages | 14 |
Journal | Expert Review of Clinical Immunology |
Volume | 6 |
Issue number | 4 |
DOIs | |
State | Published - Jul 2010 |
Keywords
- Crohns disease
- infusion reaction
- monoclonal antibody
- tumor necrosis factor
- ulcerative colitis